Mabwell announces IND application acceptance for CDH17-targeting ADC 7MW4911 from both NMPA and FDA

CAR-T Digest - August 2020

01 August 2025: Mabwell announces IND application acceptance for CDH17-targeting ADC 7MW4911 from both NMPA and FDA

Mabwell’s proprietary CDH17-targeting ADC 7MW4911 received IND acceptance from China’s NMPA and IND acknowledgement from the U.S. FDA
Developed on the IDD platform, 7MW4911 combines a specific CDH17 antibody (Mab0727), a novel cleavable linker, and the proprietary MF-6 DNA topoisomerase I inhibitor payload designed to overcome multidrug resistance
Preclinical data showed potent tumor-selective cytotoxicity, with a homogeneous DAR=4, high plasma stability, and strong bystander killing in colorectal, gastric, and pancreatic cancer models, including RAS/BRAF mutations
Demonstrated superiority over MMAE/DXd-based ADCs in ABC transporter–mediated MDR models and maintained activity in tumors with low-to-moderate CDH17 expression